Proximal Duodenal Perforation in Three Dogs Following Deracoxib Administration
Proximal Duodenal Perforation in Three Dogs Following Deracoxib Administration
复制标题
DOI：
10.5326/0460255
复制
发表时间：
2010-07-01
影响因子：
1.3
通讯作者：
Rooney, Matthew B.
中科院分区：
文献类型：
--
作者：
Case, J. Brad;Fick, Jennifer L.;Rooney, Matthew B.
本研究的目的是描述三只接受地拉昔布的犬的临床和大体病理学结果、治疗和结局，这些犬发生了近端十二指肠穿孔和随后的脓毒性腹膜炎。临床结果是在开始地拉昔布治疗后出现急性呕吐和厌食。地拉昔布剂量范围为2 - 3 mg/kg/os q 24小时。在每只狗中，剖腹探查发现十二指肠穿孔，距离十二指肠大乳头约1厘米。三只犬中有两只在剖腹探查术后存活。在本病例系列中，三只犬中的两只接受了批准的地拉昔布剂量。狗接受地拉考昔，即使在标签剂量，应审慎监测胃肠道疾病的迹象。《美国动物医院杂志》，2010年; 46：255-258。
The purpose of this study was to describe the clinical and gross pathological findings, treatment, and outcome in three dogs receiving deracoxib that developed proximal duodenal perforation and subsequent septic peritonitis. Clinical findings were acute vomiting and anorexia following initiation of deracoxib therapy. Deracoxib dosages ranged from 2 to 3 mg/kg per os q 24 hours. In each dog, exploratory laparotomy revealed duodenal perforations approximately 1 cm orad to the major duodenal papilla. Two out of three dogs survived following exploratory laparotomy. Two of three dogs in the present case series received the approved deracoxib dosage. Dogs receiving deracoxib, even at labeled dosages, should be monitored judiciously for signs of gastrointestinal disease. J Am Anim Hosp Assoc 2010; 46: 255-258.